Connect Biopharma Holdings Limited (CNTB) fundamentals score
Connect Biopharma, headquartered in San Diego, California, is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (“COPD”). The Company is advancing rademikibart, a next-generation, potentially best-in-class antibody designed to target interleukin-4-receptor alpha (“IL-4Rα”).
Pharmaceutical Preparations · Healthcare · Listed on NASDAQ
Overall: 4.7 out of 10, Weak long-term fundamentals
- Growth: 5.8/10
- Profitability: 3.3/10
- Financial health: 5.4/10
- Earnings quality: 4.2/10
- Valuation: 4.8/10
Scores are calculated from Connect Biopharma Holdings Limited’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10